China and India are the only two major countries that have been willing to export vaccines while also vaccinating their own people. Meanwhile, to rich countries, the billions of dollars of vaccine market for Big Pharma far outweigh the benefits of saving millions of lives
Bharat Biotech has claimed in a press release that its Covid-19 vaccine candidate, Covaxin, showed 81% efficacy in the “first interim analysis” of phase-3 trials.
The recent regulatory clearance given to an indigenous developed vaccine candidate in India is an example of vaccine nationalism at its worst and jettisoning of all the principles of an evidence-based, scientific approach
India’s mass vaccination plans may fail if it does not hold open discussions on its plans with health professionals and the people
The new vaccine candidate by Moderna Inc, called mRNA-1273, has reportedly shown 94.5% efficacy against the SARS-CoV-2 in the phase III clinical trials